Piper Jaffray analyst Joshua Schimmer says that while bluebird bio's updated sickle cell patient data presented over the weekend will likely "create turbulence" in shares this week, he remains "more confident than ever" that the company's "future remains bright." bluebird showed early data for four sickle cell patients treated with LentiGlobin at the American Society of Hematology meeting, Schimmer tells investors in a research note. One did "quite well," while the other three have had low Vector Copy Number and/or suboptimal myeloablation/chimerism, Schimmer writes. He points out, however, that two sickle patients with low VCN may be a result of center-specific cell handling. Schimmer reiterates an Overweight rating on bluebird shares with a $204 price target. The stock is trading down $27.66 to $56.00 in the pre-market.